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Abstract
Objective To compare the effects on proteinuria and blood pressure of
addition of dietary sodium restriction or angiotensin receptor blockade
at maximum dose, or their combination, in patients with non-diabetic
nephropathy receiving background treatment with angiotensin converting
enzyme (ACE) inhibition at maximum dose.
Design Multicentre crossover randomised controlled trial.
Setting Outpatient clinics in the Netherlands.
Participants 52 patients with non-diabetic nephropathy.
Interventions All patients were treated during four 6 week periods, in
random order, with angiotensin receptor blockade (valsartan 320 mg/day)
or placebo, each combined with, consecutively, a low sodium diet (target
50 mmol Na
+/day) and a regular sodium diet (target 200 mmol Na
+/day),
with a background of ACE inhibition (lisinopril 40 mg/day) during the
entire study. The drug interventions were double blind; the dietary
interventions were open label.
Main outcome measures The primary outcome measure was
proteinuria; the secondary outcome measure was blood pressure.
Results Mean urinary sodium excretion, a measure of dietary sodium
intake, was 106 (SE 5) mmol Na
+/day during a low sodium diet and 184
(6) mmol Na
+/day during a regular sodium diet (P<0.001). Geometric
mean residual proteinuria was 1.68 (95% confidence interval 1.31 to
2.14) g/day during ACE inhibition plus a regular sodium diet. Addition
of angiotensin receptor blockade to ACE inhibition reduced proteinuria
to 1.44 (1.07 to 1.93) g/day (P=0.003), addition of a low sodium diet
reduced it to 0.85 (0.66 to 1.10) g/day (P<0.001), and addition of
angiotensin receptor blockade plus a low sodium diet reduced it to 0.67
(0.50 to 0.91) g/day (P<0.001). The reduction of proteinuria by the
addition of a low sodium diet to ACE inhibition (51%, 95% confidence
interval 43% to 58%) was significantly larger (P<0.001) than the reduction
of proteinuria by the addition of angiotensin receptor blockade to ACE
inhibition (21%, (8% to 32%) and was comparable (P=0.009, not
significant after Bonferroni correction) to the reduction of proteinuria by
the addition of both angiotensin receptor blockade and a low sodium
diet to ACE inhibition (62%, 53% to 70%). Mean systolic blood pressure
was 134 (3) mm Hg during ACE inhibition plus a regular sodium diet.
Mean systolic blood pressure was not significantly altered by the addition
of angiotensin receptor blockade (131 (3) mm Hg; P=0.12) but was
reduced by the addition of a low sodium diet (123 (2) mm Hg; P<0.001)
and angiotensin receptor blockade plus a low sodium diet (121 (3) mm
Hg; P<0.001) to ACE inhibition. The reduction of systolic blood pressure
by the addition of a low sodium diet (7% (SE 1%)) was significantly larger
(P=0.003) than the reduction of systolic blood pressure by the addition
of angiotensin receptor blockade (2% (1)) and was similar (P=0.14) to
the reduction of systolic blood pressure by the addition of both
angiotensin receptor blockade and low sodium diet (9% (1)), to ACE
inhibition.
Conclusions Dietary sodium restriction to a level recommended in
guidelines was more effective than dual blockade for reduction of
proteinuria and blood pressure in non-diabetic nephropathy. The findings
support the combined endeavours of patients and health professionals
to reduce sodium intake.
Trial registration Netherlands Trial Register NTR675.
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Research
RESEARCHIntroduction
In patients with chronic kidney disease, blockade of the
renin-angiotensin-aldosterone system with an angiotensin
converting enzyme (ACE) inhibitor or angiotensin receptor
blockerprovideslongtermrenalandcardiovascularprotection,
apparently through the effects on blood pressure and
proteinuria.
1-3 On the basis of the finding that outcome is related
to the achieved blood pressure and proteinuria,
4-6 guidelines
recommend a blood pressure below 125/75 mm Hg in patients
with residual proteinuria exceeding 1.0 g/day, with reduction
of proteinuria to below 1.0 g/day as an independent target.
4 7
Blockade of the renin-angiotensin-aldosterone system with
monotherapy seems to be insufficiently effective for a large
proportionofpatients.
8 9Severalpotentialstrategiesaimtolower
blood pressure and proteinuria on top of ACE inhibition or
angiotensin receptor blockade.
7 10 11 These include increasing
the dose to higher than the top of the dose-response curve for
blood pressure for a better antiproteinuric response,
12-14 addition
ofasecondrenin-angiotensin-aldosteronesystemblocker(dual
blockade),
8 14 15 and correction of excess extracellular volume
by dietary sodium restriction, diuretics, or both.
16-24 Several
studies in chronic kidney disease have shown an added effect
of dual blockade on blood pressure and proteinuria,
8 14 15 but
this effect is very modest if dose titration of the single drugs
was sufficient,
25 and the long term effect is still unclear.
26 27
Addition of dietary sodium restriction might be more effective
thandualblockadeandisrationalbecausedietarysodiumintake
in patients with renal disease is usually considerably above the
recommendedvalues.
28-30However,theeffectsofdietarysodium
restrictionanddualblockadehavenotbeentestedheadtohead.
Therefore, we tested head to head which of the two additional
interventions—dietary sodium restriction and angiotensin
receptor blockade—is more effective in reaching the treatment
targets for proteinuria and blood pressure in patients with renal
disease already treated with ACE inhibition at the maximum
recommendeddose.Wealsoevaluatedtheefficacyofcombining
dietary sodium restriction and dual blockade.
Methods
Study design
The HOlland NEphrology Study (HONEST) Group did a
randomised, double blind, placebo controlled, crossover trial
between April 2006 and October 2009 in three medical centres.
The primary outcome measure of the trial was proteinuria, and
the secondary outcome measure was blood pressure. All
participants gave written informed consent. The study sponsor
provided trial drugs at no cost.
Participants
Wescreenedconsecutivepatientswithrenaldiseasewhovisited
thenephrologyoutpatientclinicsforthepresenceofnon-diabetic
nephropathy, as confirmed by analysis of blood and urine or
renal biopsy. Inclusion criteria were blood pressure above
125/75 mm Hg in combination with residual proteinuria above
1.0 g/day during ACE inhibition at maximal dose (lisinopril 40
mg/day), creatinine clearance of 30 mL/min or above, and age
over 18 years. For safety reasons, we excluded patients with
systolic blood pressure of 180 mm Hg or above, diastolic blood
pressure of 110 mm Hg or above, or both. Other exclusion
criteria were diabetes mellitus, renovascular hypertension,
decrease of creatinine clearance by at least 6 mL/min in the
previousyear,acardiovasculareventintheprevioussixmonths,
immunosuppressive treatment, regular use (>1 day/week) of
non-steroidal anti-inflammatory drugs, pregnancy, or breast
feeding.
Treatment
During a run-in period of at least six weeks, patients received
ACE inhibition at maximal dose (lisinopril 40 mg/day) and
stoppedallotherrenin-angiotensin-aldosteronesystemblockers.
Additionalantihypertensivedrugssuchasβblockers,αblockers,
calcium channel blockers, and diuretics were allowed and kept
stable during the study (table 1). No dietary intervention took
place during the run-in period.
After the run-in period, patients were treated during four
treatment periods of six weeks with, consecutively, ACE
inhibition at maximal dose (lisinopril 40 mg/day) plus placebo
and ACE inhibition plus angiotensin receptor blockade at
maximaldose(lisinopril40mg/dayplusvalsartan320mg/day).
Both treatments were combined with, consecutively, a low
sodium diet (target sodium intake 50 mmol Na
+/day;
approximately1200mgNa
+/dayor3gNaCl/day)andaregular
sodium diet (target sodium intake 200 mmol Na
+/day; 4800 mg
Na
+/dayor12gNaCl/day).Thedruginterventionsweredouble
blind, whereas the dietary interventions were open label.
Topreventsystematicerrorsresultingfromthecrossoverdesign,
the different treatment periods were done in random order.
Because of this randomisation and the rather short half life of
the interventions (lisinopril 12.6 hours, valsartan 9 hours, low
sodium diet <1 week
31), the protocol did not include wash-out
periods.
We defined four different treatment sequences as follows. (1)
Placebo plus low sodium diet, valsartan plus low sodium diet,
valsartanplusregularsodiumdiet,placeboplusregularsodium
diet.(2)Placeboplusregularsodiumdiet,valsartanplusregular
sodium diet, valsartan plus low sodium diet, placebo plus low
sodium diet. (3) Valsartan plus regular sodium diet, placebo
plusregularsodiumdiet,placebopluslowsodiumdiet,valsartan
plus low sodium diet. (4) Valsartan plus low sodium diet,
placebopluslowsodiumdiet,placeboplusregularsodiumdiet,
valsartan plus regular sodium diet. An independent pharmacist
randomised these sequences, using a computer program. We
implemented the random allocation sequence by means of
sequentially numbered containers of study drug. Physicians
enrolled patients, and the pharmacist allocated the study drug
sequentially to consecutive participants. The randomisation
code remained secret during the entire study; all participants,
investigators, and care providers were blinded, except for the
pharmacist.
Physicians gave the participants a list of food products that are
commonly consumed in the Netherlands, together with their
sodium content, at the time of inclusion. Diverse professional
dietitiansgavefurtherdietarycounsellinginvariousautonomous
dietary practices in the community. Except for a request to
achieve the particular sodium targets (that is, 50 mmol Na
+/day
during the low sodium diet and 200 mmol Na
+/day during the
regular sodium diet), dietitians did not receive extra training or
a script for this study. Each patient had two to four dietary
counsellingsessions.Individualisedcounsellingusedthegeneral
principle of remaining as close as possible to the patients’
preferences and nutritional habits, to increase feasibility and
compliance, taking into account adequacy of nutritional
requirements as well as sodium content. For the periods on the
regular sodium diet, the patients were advised to maintain their
habits regarding sodium intake. For the periods on the low
sodium diet, patients were advised not to add any salt to their
food and to replace sodium rich products with sodium poor
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RESEARCHproducts.Wemonitoredcomplianceby24hoururinarysodium
excretion and informed the physician, patients, and dietitians
of these results.
Measurements and calculations
At the end of each six week treatment period, patients collected
24 hour urine samples and blood pressure was measured and
blood sampled after an overnight fast. Additionally, in the
middle of every six week treatment period, patients collected
24 hour urine samples to monitor dietary compliance.
We measured proteinuria in 24 hour urine samples with a
turbidimetric assay using benzethonium chloride (Modular,
RocheDiagnostics,Mannheim,Germany).Wemeasuredblood
pressure at one minute intervals with an automatic device
(Dinamap, G E Medical Systems, Milwaukee, WI, USA) with
the patient in a supine position. After 15 minutes of
measurements, we used the mean of the last three readings for
further analysis. We determined blood electrolytes, lipids,
proteins, and urinary electrolytes by using an automated
multianalyser (Modular, Roche Diagnostics, Mannheim,
Germany). We assessed dietary sodium intake from urinary
sodium excretion. We calculated creatinine clearance from
creatinine concentrations in plasma and in 24 hour urine
samples. We used the Maroni formula to assess dietary protein
intake from urinary urea excretion.
32 33 We assessed peripheral
pitting oedema at the pretibial area of both legs by visual and
manual examination and scored it as absent or present.
Statistical analysis
Weexpectedthatpatientswouldpresentwithameanproteinuria
of approximately 2 g/day during ACE inhibition. On the basis
of previous studies, we assumed a 35% reduction in proteinuria
by addition of a low sodium diet on top of ACE inhibition plus
angiotensin receptor blockade and a standard deviation of 0.75
in log transformed proteinuria response.
8 25 16 17 20 From these
numbers, we estimated that 51 patients had to complete the
crossover design to provide 90% power to detect a statistically
significantdifference.Weusedasignificancelevelofα=0.0083
(rather than α=0.05) to adjust for six primary comparisons of
interest. To account for a 10% dropout rate during the trial, we
would need to include 56 patients (PASS 10, NCCS, East
Kaysville, UT, USA). Of note, the sample size is smaller than
would have been needed in a non-crossover study, as the same
patientprovidesdataforeachtreatmentgroupandthisincreases
power, owing to the smaller within patient variability than
between group variability.
34 35
We analysed data for the 52 patients who completed the trial,
and we present these data here. Additionally, we analysed the
data for all 54 patients who were included (intention to treat).
As the effect estimates and confidence intervals were very
similar and the statistical and clinical conclusions did not
change,wehavenotshownthesedata.Beforestatisticaltesting,
wenaturallogtransformedskewedvariablestoobtainnormality.
Wedetermineddifferencesbetweenthefourdifferenttreatment
sequences by using one way analysis of variance with
Bonferroni’s post hoc tests and Pearson’s χ
2 tests. We used
paired t tests (which account for the same patients providing
data for both treatment groups) to determine the effects of
treatment. We did six comparisons for each parameter: ACE
inhibition versus ACE inhibition plus angiotensin receptor
blockade, ACE inhibition versus ACE inhibition plus low
sodium diet, ACE inhibition versus ACE inhibition plus
angiotensin receptor blockade plus low sodium diet, ACE
inhibition plus angiotensin receptor blockade versus ACE
inhibitionpluslowsodiumdiet,ACEinhibitionplusangiotensin
receptor blockade versus ACE inhibition plus angiotensin
receptor blockade plus low sodium diet, and ACE inhibition
plus low sodium diet versus ACE inhibition plus angiotensin
receptor blockade plus low sodium diet. To allow for multiple
testing, we set the type I error (α) at 0.0083 (Bonferroni
correction) for analyses of the primary outcome (proteinuria).
Furthermore, we did a linear mixed model analysis to check for
carryover effects, with log transformed proteinuria as a
dependent variable, participants as a random factor, and
treatment and sequence as well as their interaction
(treatment*sequence) as fixed factors.
We give data as mean with standard error (SE) when normally
distributed or as geometric mean with 95% confidence interval
when skewed. We report only unadjusted P values. We used
SPSS 16.0 for Windows for all analyses.
Results
Study population
We assessed 71 patients for eligibility. Of these, 13 patients
declined to participate and 58 patients gave informed consent
and started the run-in period. During the run-in period, two
patients discontinued because of symptomatic hypotension and
two patients were withdrawn because of complete reduction of
proteinuria.Ofthe54patientswhowererandomised,onepatient
was withdrawn because of a rash after starting valsartan and
onepatientdiscontinuedbecauseoflackofmotivationtoadhere
tothelowsodiumdiet.Finally,52patientscompletedthestudy
and were included in the analyses. Table 1 shows baseline
characteristics. Non-study drugs were kept stable during the
study.
Before entry into the study, 14 of the 52 patients used a β
blocker, whereas 12 patients were using a β blocker at the end
of the run-in period (and during the rest of the study). The
equivalent numbers were 10 versus 10 patients for calcium
channel blockers, 5 versus 6 for α blockers, 24 versus 8 for
thiazide diuretics, 9 versus 5 for loop diuretics, 36 versus 52
for ACE inhibitors, and 29 versus 0 for angiotensin receptor
blockers.
Compliance and efficacy
We assessed compliance from 24 hour urine samples and from
pillcounts.Urinarycreatinineexcretionwascomparableduring
all treatment periods, indicating accurate 24 hour urine sample
collection (table 2). Mean dietary sodium intake, as assessed
from urinary sodium excretion, was 106 (SE 5) mmol Na
+/day
(approximately 2500 mg Na
+/day or 6 g NaCl/day) during the
periods on a low sodium diet and 184 (6) mmol Na
+/day (4400
mg Na
+/day or 11 g NaCl/day; P<0.001 v low sodium diet)
during the periods on the regular sodium diet. All patients
adhered to the pharmaceutical intervention (>85% of valsartan
and placebo capsules taken during each study period), except
for two patients who took only 60-70% of the blinded study
drug during the four different treatment periods. We included
all 52 patients in the analyses.
The addition of a low sodium diet to ACE inhibition decreased
body weight (from mean 89 (SE 3) kg to 87 (2) kg; P<0.001)
andplasmasodium(from140.7(SE0.4)mmol/Lto139.5(0.4)
mmol/L; P=0.001) and tended to reduce the prevalence of
peripheral oedema (from 18 (35%) patients to 8 (15%);
P=0.057), and increased plasma albumin (from 38 (1) g/L to 40
(1) g/L; P<0.001) and total protein (from 68 (1) g/L to 71 (1)
g/L; P<0.001), consistent with a negative sodium balance.
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RESEARCHAddition of angiotensin receptor blockade to ACE inhibition
didnotaffecttheseparameters,whereasadditionofangiotensin
receptorblockadeplusalowsodiumdiettoACEinhibitionhad
approximately the same effect as addition of a low sodium diet
alone (table 2). Dietary protein intake, as assessed from urinary
ureaexcretion,was1.02(0.04)g/kg/dayduringACEinhibition.
It was not altered by the addition of angiotensin receptor
blockade(1.01(0.04)g/kg/day;P=0.99)butwasslightlyreduced
by the addition of a low sodium diet (0.96 (0.04) g/kg/day;
P=0.004) or a low sodium diet plus angiotensin receptor
blockade (0.91 (0.03) g/kg/day; P<0.001) to ACE inhibition.
Proteinuria (primary outcome)
During ACE inhibition combined with the regular sodium diet,
geometricmeanresidualproteinuriawas1.68(95%confidence
interval 1.31 to 2.14) g/day (fig 1). Addition of angiotensin
receptor blockade reduced proteinuria to 1.44 (1.07 to 1.93)
g/day (P=0.003), and addition of a low sodium diet reduced it
to 0.85 (0.66 to 1.10) g/day (P<0.001). The lowest level of
residual proteinuria (0.67 (0.50 to 0.91) g/day; P<0.001) was
achieved by the addition of angiotensin receptor blockade plus
a low sodium diet. Moreover, the reduction of proteinuria by
the addition of a low sodium diet to ACE inhibition (reduction
of51%(95%confidenceinterval43%to58%)wassignificantly
larger(P<0.001)thanthereductionofproteinuriabytheaddition
of angiotensin receptor blockade to ACE inhibition (reduction
of 21% (8% to 32%). However, the reduction of proteinuria by
the addition of both a low sodium diet and angiotensin receptor
blockade to ACE inhibition (reduction of 62% (53% to 70%)
was not significantly larger (P=0.009, not significant after
Bonferroni correction) than the reduction of proteinuria by the
addition of only a low sodium diet to ACE inhibition. In an
additionallinearmixedmodelanalysis,weverifiedtheabsence
of carryover effects. Treatment was a significant determinant
of residual proteinuria (P<0.001), whereas sequence (P=0.52)
and treatment*sequence (P=0.98) were not. We found similar
results for urinary protein/creatinine ratio (table 2).
Secondary outcomes
Systolic and diastolic blood pressure were above the target of
125/75mmHgduringACEinhibitioncombinedwiththeregular
sodium diet. Mean systolic blood pressure was 134 (SE 3) mm
Hg during ACE inhibition (fig 2). Addition of angiotensin
receptor blockade did not significantly alter systolic blood
pressure (131 (3) mm Hg; P=0.12), whereas addition of a low
sodium diet reduced systolic blood pressure to 123 (2) mm Hg
(P<0.001) and addition of both angiotensin receptor blockade
and a low sodium diet reduced systolic blood pressure to 121
(3)mmHg(P<0.001).Moreover,thereductionofsystolicblood
pressure by the addition of a low sodium diet to ACE inhibition
(reduction of 7% (SE 1%)) was significantly larger (P=0.003)
than that achieved by the addition of angiotensin receptor
blockade to ACE inhibition (reduction of 2% (1%)). However,
the reduction of systolic blood pressure by the addition of both
a low sodium diet and angiotensin receptor blockade to ACE
inhibition (reduction of 9% (1%)) was not significantly larger
(P=0.14)thanthatachievedbytheadditionofonlyalowsodium
diet to ACE inhibition (reduction of 7% (1%)).
Mean diastolic blood pressure was 80 (SE 2) mm Hg during
ACE inhibition combined with the regular sodium diet (fig 3).
Diastolic blood pressure was slightly reduced by the addition
of angiotensin receptor blockade (77 (2) mm Hg; decrease of
4% (2%); P=0.02) and was considerably reduced by addition
of a low sodium diet (73 (2) mm Hg; decrease of 8% (2%);
P<0.001) and by the addition of angiotensin receptor blockade
plus a low sodium diet (71 (2) mm Hg; decrease of 11% (2%);
P<0.001).
Renal function was relatively preserved during ACE inhibition
combined with the regular sodium diet (geometric mean
creatinine clearance 72 (62 to 84) mL/min; mean plasma
creatinine137(8)µmol/L).Renalfunctionwasnotsignificantly
altered by the addition of angiotensin receptor blockade
(creatinine clearance 74 (65 to 84) mL/min; P=0.65), but
decreased when a low sodium diet (66 (57 to 76) mL/min;
P=0.002) or angiotensin receptor blockade plus a low sodium
diet (61 (53 to 70) mL/min; P<0.001) was added to ACE
inhibition; this effect was reversible on withdrawal of the low
sodium diet and angiotensin receptor blockade (not shown).
Mean plasma potassium was 4.6 (0.1) mmol/L during ACE
inhibition combined with the regular sodium diet and was not
significantly changed by the addition of angiotensin receptor
blockade(4.6(0.1)mmol/L;P=0.09),whereasadditionofalow
sodiumdiet(4.7(0.1)mmol/L;P=0.03)orangiotensinreceptor
blockade plus a low sodium diet (5.0 (0.1) mmol/L; P<0.001)
increased plasma potassium concentrations. Potassium
concentrations in the lower range (<4.0 mmol/L) were present
in eight patients during ACE inhibition combined with the
regular sodium diet and in two patients during ACE inhibition
plus angiotensin receptor blockade plus a low sodium diet.
Potassium concentrations in the higher range (>5.5 mmol/L)
were present in three patients during ACE inhibition combined
with the regular sodium diet and in 10 patients during ACE
inhibitionplusangiotensinreceptorblockadeplusalowsodium
diet.
Severe orthostatic complaints occurred in two patients during
the first treatment period, which was ACE inhibition plus
angiotensin receptor blockade plus low sodium diet for one
patient and ACE inhibition plus low sodium diet for the other.
The complaints were resolved by tapering of lisinopril to 20
mg/day. In these patients, the dose of lisinopril was kept stable
at 20 mg/day during the rest of the treatment periods. In five
other patients, mild orthostatic complaints not necessitating
drug withdrawal occurred: in three patients during ACE
inhibition plus angiotensin receptor blockade plus low sodium
dietandintwopatientsduringACEinhibitionpluslowsodium
diet. Dry cough occurred in one patient and was present during
allstudyperiods.ThesecomplaintsresolvedontaperingofACE
inhibition after the last study period.
Discussion
This study provides the first head to head comparison of
moderatedietarysodiumrestriction,add-onangiotensinreceptor
blockade, and their combination, as measures to improve the
therapeutic effect of angiotensin converting enzyme (ACE)
inhibition. In patients with non-diabetic renal disease with
insufficient control of proteinuria and blood pressure despite
maximally dosed ACE inhibition monotherapy, addition of
maximally dosed angiotensin receptor blockade had a modest
added effect on proteinuria, without effects on systolic blood
pressure. Addition of a low sodium diet to ACE inhibition
induced a considerable reduction of proteinuria and blood
pressure, and a slight additional reduction of proteinuria
occurredduringalowsodiumdietcombinedwithdualblockade.
Thesedatashow,firstly,thatmoderatedietarysodiumrestriction
added to ACE inhibition is more effective to reach proteinuria
and blood pressure targets than is dual blockade and, secondly,
that a low sodium diet also improves proteinuria and blood
pressure during dual blockade.
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RESEARCHComparison with other studies
Our findings on dual blockade and a low sodium diet are in line
withpreviousstudiesinchronickidneydisease.Ameta-analysis
found no differences in systolic and diastolic blood pressure
betweenACEinhibitionplusangiotensinreceptorblockadeand
ACE inhibition alone.
15 In another meta-analysis, proteinuria
wasonaverage22%(16%to28%)lowerduringACEinhibition
plusangiotensinreceptorblockadethanduringACEinhibition.
8
In previous studies of dietary sodium intervention, blood
pressurewasonaverage3%to9%lowerduringACEinhibition
(orangiotensinreceptorblockade)combinedwithalowsodium
diet than during ACE inhibition (or angiotensin receptor
blockade)combinedwitharegularsodiumdiet,andproteinuria
was 31% to 40% lower.
16 17 20 21 In these studies, the urinary
sodium excretion, reflecting dietary sodium intake, was in the
same range as in our study, supporting the generalisability of
our findings in renal populations.
Other outcome measures
Plasma potassium concentrations were unaffected by addition
ofangiotensinreceptorblockadetoACEinhibitionbutincreased
by addition of a low sodium diet or angiotensin receptor
blockade plus a low sodium diet. This may be relevant given
the previously shown U shaped relation between plasma
potassium and outcome in patients with renal disease, with a
higher risk of end stage renal disease and death at potassium
concentrations below 4.0 mmol/L and a higher risk of
cardiovascular events and death at concentrations exceeding
5.5 mmol/L.
36 37 Increases in potassium might be beneficial in
patients with initial plasma potassium in the lower range (15%
of our patients) and a potential threat in patients with initial
plasma potassium in the higher range (6% of our patients) and
would require careful monitoring.
Renal function was not significantly altered by addition of
angiotensin receptor blockade to ACE inhibition but decreased
by addition of a low sodium diet or angiotensin receptor
blockade plus a low sodium diet. This decline in renal function
was reversible and probably reflects a fall in glomerular
pressure. No evidence suggests that such an effect is harmful;
in contrast, it has been associated with a slower subsequent
decline in renal function.
38-41 This relation between a treatment
induced short term decline in renal function and long term
preservation of renal function seems to hold for increases in
plasma creatinine of up to 30% in people with creatinine
exceeding 124 µmol/L (1.4 mg/dL),
40 which was the case in our
patients.
Orthostatic complaints occurred in seven of our 52 patients,
during the regimens with the strongest antihypertensive effect
(that is, during dual or single blockade combined with the low
sodium diet but not during the regular sodium diet). Only two
patients needed tapering of ACE inhibition.
Diuretic treatment
The effect of a low sodium diet added to ACE inhibition is
probablyduetoacorrectionofexcessextracellularvolume.An
alternative approach is diuretic treatment or combination
treatment.
16 17 19 21Interestingly,up-titrationofdiureticcombined
with half doses of ACE inhibition plus angiotensin receptor
blockade was recently found to reduce proteinuria better than
ACEinhibitionplusup-titrationofangiotensinreceptorblockade
to full dose.
42 Moreover, we previously showed that the
combination of a low sodium diet and diuretics was more
effective than either alone.
16 In this study, we applied only the
low sodium diet, but patients who needed diuretics during the
run-in period to control oedema continued this treatment at a
fixed dose. For the treatment protocol, we refrained from
combining a low sodium diet and diuretics to avoid excessive
volume depletion, and associated adverse effects on blood
pressureandrenalfunction,duringthemaximalpharmacological
blockade of the renin-angiotensin-aldosterone system. Thus, in
individual patients with insufficient response to dual blockade
plusalowsodiumdiet,theresponsecouldprobablybeimproved
by adding a diuretic, with monitoring of tolerability.
Strengths and limitations of study
This study provides the first head to head comparison of
moderatedietarysodiumrestriction,add-onangiotensinreceptor
blockade, and their combination, as measures to improve the
therapeutic effect of ACE inhibition. We selected patients with
high residual risk during ACE inhibition monotherapy, which
is precisely the target population for added measures and thus
clinicallyrelevant.
8 9Reductionofbloodpressureandproteinuria
in the range seen here has previously been shown to predict a
better renal and cardiovascular outcome.
2 3 6
We aimed to optimise the applicability of our results to clinical
practicebydoingthedietaryinterventioninanoutpatientsetting
that reflects the usual nephrology care, with relatively simple
dietary measures, replacing sodium rich food components with
sodium poor products. In line with previous studies, regular
sodiumintakewaswellabovetherecommendedintake.
28-30Our
dietaryinterventionpolicydidnotresultinthetargetof50mmol
Na
+/day, but a substantial reduction in sodium intake to values
in line with the guidelines for renal patients was nevertheless
achieved.
43 This supports the applicability of our results to
clinical practice.
Furthermore, we used maximal doses of ACE inhibition and
angiotensinreceptorblockadetoensureamaximaleffectofthe
dual blockade on both blood pressure and proteinuria, because
sub-maximal dosing hampers interpretation of many studies on
dual blockade. Thus, the stronger effect of the low sodium diet
cannot be attributed to a suboptimal dual blockade regimen.
The main limitation of the study is that it provides only short
term data and no hard end points. Also, the population was
relatively small, although this is the largest study of sodium
intervention in proteinuric patients so far. Furthermore, we
excluded patients with diabetes because of possible
heterogeneityintherenalresponsetosodiumrestriction.
44These
characteristics limit the generalisability of our data. Of note, a
separate study in patients with diabetic proteinuria is ongoing
(trial number NTR2366, www.trialregister.nl/trialreg/admin/
rctsearch.asp?Term=dinamo).
Thesodiuminterventionwasdoneinawaythatcloselymimics
clinical care in the outpatient setting. For the periods on the
regular sodium diet, the patients were advised to maintain their
habits regarding sodium intake. For the periods on the low
sodium diet, patients were advised not to add any salt to their
food and to replace sodium rich products with sodium poor
products.Accordingly,thelowerproteinuriaandbloodpressure
cannot specifically be attributed to the lower sodium intake, as
inadvertent changes in other food components might be
involved. However, such changes are likely to occur in clinical
practice as well.
From the relevant food components that could be documented
in 24 hour urine samples, potassium intake did not change.
Urinaryureaexcretionwasreducedduringthelowsodiumdiet,
suggesting a somewhat lower protein intake. Hence, a lower
protein intake may have contributed to the beneficial effect on
proteinuria,
45 46althoughthedirecteffectofthelowsodiumdiet
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seems likely to be the main driving force for reduction in
proteinuria. Urinary calcium excretion was lower during low
sodiumperiods.Wecannotexcludealowercalciumintake,but
the lower calciuria is in line with corresponding findings in
other populations, where it is attributed to altered renal calcium
handling.
47 At any rate, the lower blood pressure during low
sodium periods is not likely to be due to an inadvertent higher
calcium intake.
Finally, as the study was not powered on blood pressure, we
cannot exclude the possibility that the absence of a significant
effectofadd-onangiotensinreceptorblockadeonbloodpressure
may be due to a lack of power.
Policy implications
Our data clearly show that a moderate restriction of dietary
sodium intake, which is feasible in routine nephrology care, is
more effective than dual renin-angiotensin-aldosterone system
blockadeforcontrolofbloodpressureandproteinuriainchronic
kidney disease, with an acceptable rate of adverse effects.
Whetherthistranslatesintoimprovedoutcomeinchronickidney
disease should be investigated in a well powered study with
sufficiently long term follow-up. This is all the more relevant
because long term results of dual blockade have turned out to
be unreliable or controversial,
26 27 48 whereas the long term
benefits of dietary sodium restriction are increasingly
appreciated.
11 49-52Ofnote,therangeofsodiumintakeassociated
withamorefavourablelongtermhealthoutcomeintheliterature
is not excessively low, with respect to both spontaneous intake
and after intervention,
28 49 51 and corresponds to level of sodium
restrictionobtainedinourstudy.Thisimpliesthatgeneralefforts
to implement guidelines for sodium intake, as recently
emphasised for the general population,
51 will have the potential
to greatly improve health outcomes in patients with chronic
renaldisease.Asrenin-angiotensin-aldosteronesystemblockade
isalsoamainstayoftreatmentinessentialhypertension,diabetic
nephropathy, and heart failure, investigating the potential of
sodium restriction to enhance the efficacy of such blockade in
these populations as well would be of great interest.
Conclusions
Moderate dietary sodium restriction was more effective than
the addition of maximal dose angiotensin receptor blockade for
control of proteinuria and blood pressure in patients with renal
disease on a maximal dose of ACE inhibition. Dual blockade
should not be instituted in the absence of adequate dietary
sodium restriction. Confirmation studies with hard end points
are necessary, but in the meantime a coordinated effort to
implement the guidelines on sodium intake is warranted. Our
findingssupportthecombinedendeavoursofpatientsandhealth
professionals to accomplish persistent sodium restriction to
improve the efficacy of renoprotective treatment.
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RESEARCHTables
Table 1| Baseline* characteristics. Values are numbers of patients unless stated otherwise
Treatment sequence†
Characteristics 4 (n=14) 3 (n=13) 2 (n=11) 1 (n=14)
47 (4) 51 (4) 55 (3) 53 (3) Mean (SE) age (years)
93 92 82 64 Male sex
14 13 11 14 White ethnicity
28 (1) 28 (1) 28 (1) 27 (1) Mean (SE) body mass index (kg/m
2)
Renal diagnosis:
6 4 2 3 IgA nephropathy
3 3 7 3 Focal segmental glomerulosclerosis
3 2 0 2 Membranous nephropathy
0 3 2 1 Hypertensive nephropathy
2 1 0 5 Other/inconclusive
Use of non-study drugs‡:
2 4 2 4 β blocker
2 3 4 1 Calcium channel blocker
1 3 1 0 α blocker
6 3 1 3 Diuretic
4 7 7 7 Lipid lowering agent
123 (4) 135 (7) 135 (4) 131 (4) Mean (SE) systolic blood pressure (mm Hg)
71 (3) 78 (4) 78 (3) 78 (2) Mean (SE) diastolic blood pressure (mm Hg)
1.5 (0.8 to 2.6) 1.5 (0.9 to 2.6) 2.0 (1.3 to 3.0) 1.5 (0.9 to 2.4) Geometric mean (95% CI) proteinuria (g/24 hours)
78 (56 to 107) 74 (56 to 98) 60 (41 to 89) 70 (56 to 88) Geometric mean (95% CI) creatinine clearance
(mL/min)
182 (22) 197 (20) 161 (14) 166 (23) Mean (SE) urinary sodium excretion (mmol/24
hours)
*Data at end of run-in period taken as baseline values.
†1=placebo-low sodium diet, valsartan-low sodium diet, valsartan-regular sodium diet, placebo-regular sodium diet; 2=placebo-regular sodium diet, valsartan-regular
sodium diet, valsartan-low sodium diet, placebo-low sodium diet; 3=valsartan-regular sodium diet, placebo-regular sodium diet, placebo-low sodium diet, valsartan-low
sodium diet; 4=valsartan-low sodium diet, placebo-low sodium diet, placebo-regular sodium diet, valsartan-regular sodium diet; no significant differences in baseline
values were found.
‡Kept stable during study.
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RESEARCHTable 2| Clinical parameters during four treatment periods. Values are mean (SE) or geometric mean (95% confidence interval)
Low sodium diet Regular sodium diet
ACE inhibitor-ARB ACE inhibitor ACE inhibitor-ARB ACE inhibitor
Plasma
139.1 (0.4)*† 139.5 (0.4)*† 140.8 (0.4) 140.7 (0.4) Sodium (mmol/L)
5.0 (0.1)*†‡ 4.7 (0.1)* 4.6 (0.1) 4.6 (0.1) Potassium (mmol/L)
157 (9)*† 149 (9)* 137 (8) 137 (8) Creatinine (µmol/L)
12.9 (0.8)*† 11.8 (0.8)*† 10.2 (0.7) 9.8 (0.7) Urea (mmol/L)
40 (1)*† 40 (1)*† 39 (1) 38 (1) Albumin (g/L)
72 (1)*† 71 (1)* 69 (1) 68 (1) Total protein (g/L)
4.9 (0.2) 4.8 (0.1) 5.0 (0.2) 5.1 (0.2) Total cholesterol (mmol/L)
Urine
13.4 (0.6) 13.5 (0.6) 14.0 (0.5) 13.8 (0.6) Creatinine (mmol/24 hours)
105 (8)*† 106 (7)*† 180 (9) 189 (8) Sodium (mmol/24 hours)
352 (19)*† 359 (17)*† 403 (19) 395 (18) Urea (mmol/24 hours)
73 (3) 76 (4) 76 (4) 78 (3) Potassium (mmol/24 hours)
0.7 (0.5 to 0.9)*† 0.7 (0.6 to 0.9)* 1.0 (0.7 to 1.3)* 1.2 (0.9 to 1.5) Calcium (mmol/24 hours)
61 (53 to 70)*† 66 (57 to 76)*† 74 (65 to 84) 72 (62 to 84) Creatinine clearance (mL/min)
0.5 (0.3 to 0.7)*†‡ 0.6 (0.4 to 0.8)*† 0.9 (0.7 to 1.3)* 1.2 (0.9 to 1.5) Protein/creatinine ratio (mg/mg)
Other
87 (2)*† 87 (2)*† 89 (2) 89 (3) Body weight (kg)
4*† 8† 20 18 Oedema (No of patients)
4 3 0 0 Symptomatic hypotension (number)
1 1 1 1 Dry cough (number)
ACE=angiotensin converting enzyme; ARB=angiotensin receptor blocker.
*P<0.01 versus ACE inhibitor on regular sodium diet.
†P<0.01 versus ACE inhibitor-ARB on regular sodium diet.
‡P<0.01 versus ACE inhibitor on low sodium diet.
Reprints: http://journals.bmj.com/cgi/reprintform Subscribe: http://resources.bmj.com/bmj/subscribers/how-to-subscribe
BMJ 2011;343:d4366 doi: 10.1136/bmj.d4366 Page 9 of 10
RESEARCHFigures
Fig 1 Additional effect of low sodium diet, angiotensin receptor blockade (ARB), or both on proteinuria during angiotensin
converting enzyme (ACE) inhibition. Data are geometric mean with 95% confidence interval. *P<0.05 v ACE inhibition on
regular sodium diet. †P<0.05 v ACE inhibition plus ARB on regular sodium diet. ‡P<0.05 v ACE inhibition on low sodium
diet
Fig 2 Additional effect of low sodium diet, angiotensin receptor blockade (ARB), or both on systolic blood pressure during
angiotensin converting enzyme (ACE) inhibition. Data are mean with 95% confidence interval. *P<0.05 v ACE inhibition on
regular sodium diet. †P<0.05 v ACE inhibition plus ARB on regular sodium diet
Fig 3 Additional effect of low sodium diet, angiotensin receptor blockade (ARB), or both on diastolic blood pressure during
angiotensin converting enzyme (ACE) inhibition. Data are mean with 95% confidence interval. *P<0.05 v ACE inhibition on
regular sodium diet. †P<0.05 v ACE inhibition plus ARB on regular sodium diet
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